Inhibition of Amyloid-β (Aβ)-Induced Cognitive Impairment and Neuroinflammation in CHI3L1 Knockout Mice through Downregulation of ERK-PTX3 Pathway
Open Access
- 19 May 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5550
Abstract
Several clinical studies reported that the elevated expression of Chitinase-3-like 1 (CHI3L1) was observed in patients suffering from a wide range of diseases: cancer, metabolic, and neurological diseases. However, the role of CHI3L1 in AD is still unclear. Our previous study demonstrated that 2-({3-[2-(1-Cyclohexen-1-yl)ethyl]-6,7-dimethoxy-4-oxo-3,4-dihydro-2-quinazolinyl}culfanyl)-N-(4-ethylphenyl)butanamide, a CHI3L1 inhibiting compound, alleviates memory and cognitive impairment and inhibits neuroinflammation in AD mouse models. In this study, we studied the detailed correlation of CHI3L1 and AD using serum from AD patients and using CHI3L1 knockout (KO) mice with Aβ infusion (300 pmol/day, 14 days). Serum levels of CHI3L1 were significantly elevated in patients with AD compared to normal subjects, and receiver operating characteristic (ROC) analysis data based on serum analysis suggested that CHI3L1 could be a significant diagnostic reference for AD. To reveal the role of CHI3L1 in AD, we investigated the CHI3L1 deficiency effect on memory impairment in Aβ-infused mice and microglial BV-2 cells. In CHI3L1 KO mice, Aβ infusion resulted in lower levels of memory dysfunction and neuroinflammation compared to that of WT mice. CHI3L1 deficiency selectively inhibited phosphorylation of ERK and IκB as well as inhibition of neuroinflammation-related factors in vivo and in vitro. On the other hand, treatment with recombinant CHI3L1 increased neuroinflammation-related factors and promoted phosphorylation of IκB except for ERK in vitro. Web-based gene network analysis and our results showed that CHI3L1 is closely correlated with PTX3. Moreover, in AD patients, we found that serum levels of PTX3 were correlated with serum levels of CHI3L1 by Spearman correlation analysis. These results suggest that CHI3L1 deficiency could inhibit AD development by blocking the ERK-dependent PTX3 pathway.Keywords
Funding Information
- Ministry of Science and ICT, South Korea (MRC, 2017R1A5A2015541, 2021RIS-001)
- Korean Government (MOE) (MRC, 2017R1A5A2015541, 2021RIS-001)
This publication has 53 references indexed in Scilit:
- Potential role of chitinase‐3‐like protein 1 (CHI3L1/YKL‐40) in neurodegeneration and Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axisHuman Cell, 2021
- Neuroinflammation, Gut Microbiome, and Alzheimer’s DiseaseMolecular Neurobiology, 2018
- Neuroinflammation in Neurodegenerative Disorders—a ReviewCurrent Neurology and Neuroscience Reports, 2017
- Inflammatory Cytokines and Alzheimer’s Disease: A Review from the Perspective of Genetic PolymorphismsNeuroscience Bulletin, 2016
- Differential Roles of M1 and M2 Microglia in Neurodegenerative DiseasesMolecular Neurobiology, 2015
- Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative OverviewMolecular Neurobiology, 2014
- YKL-40 is elevated in patients with peripheral arterial disease and diabetes or pre-diabetesAtherosclerosis, 2012
- Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: Decreased tumor metastasis in a breast cancer modelInternational Journal of Cancer, 2011
- Developments of a water-maze procedure for studying spatial learning in the ratJournal of Neuroscience Methods, 1984